ACLA Aclara Biosciences, (MM)

ACLARA to Host Investor Briefing and Webcast at ASCO Annual Meeting Monday June 7, 2004 at 7:00 A.M. Central time MOUNTAIN VIEW, Calif., June 3 /PRNewswire-FirstCall/ -- ACLARA BioSciences (NASDAQ:ACLA) will conduct an investor briefing to provide an overview of the company's protein-based molecular diagnostics technology, the eTag(TM) System, at the American Society of Clinical Oncology Meeting (ASCO) on Monday, June 7 at 7:00 a.m. Central Time at the Embassy Suites Hotel, 315 Julia Street, New Orleans in the Andrew Jackson Board Room. The briefing will be hosted by Thomas Klopak, ACLARA's chief executive officer and Dr. Sharat Singh, ACLARA's chief technical officer and inventor of the eTag technology. Members of the Company's Scientific Advisory Board, Dr. David Agus, M.D., and Dr. Carlos Arteaga, M.D., will also be available to answer questions regarding their respective scientific work. Dr. Agus, Research Director at the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center and Assistant Professor of Medicine at UCLA, is researching the various factors that influence cancer development, progression and response to treatment. Dr. Arteaga, Professor of Medicine and Cancer Biology and Director of the Breast Cancer Research Program of the Vanderbilt-Ingram Cancer Center at Vanderbilt University School of Medicine is distinguished for his studies of the HER2 receptor. Investor Briefing Webcast and Conference Call Details Those wishing to participate in the Investor Briefing via live teleconference should call 800-289-0494 several minutes before 7 a.m. Central Time, Monday June 7. In addition, the audio and slide presentations from the briefing will be simultaneously broadcast over the Internet and will be available to investors, news media and the general public. The live and archived webcast can be accessed by going to Investor Relations section at http://www.aclara.com/ and clicking on the Conference Calls link. The webcast will be archived on the ACLARA website. For those who are not able to access the live conference, an audio replay will be available until Wednesday June 9, 2004 by dialing 888-203-1112 (U.S.) or 719-457-0820 (international) and giving the following confirmation code: 643288 for access. About ACLARA Founded in 1995, ACLARA is a biotechnology company working to provide physicians and researchers products and services to make personalized medicine a reality through its protein-based assay technology -- the eTag(TM) System. ACLARA is dedicated to unlocking the power of pathway biology to accelerate the development of next-generation targeted therapeutics, recognizing the most appropriate patients for approved therapies and identifying the highly-specific, protein-based biomarkers that will enable physicians to create truly personalized treatment regimens for patients suffering from cancer and other life-threatening disorders. ACLARA is commercializing its proprietary eTag System to enhance and accelerate drug discovery research and the preclinical and clinical development of targeted therapeutics. ACLARA's technology may also enable the development of highly-specific, protein-based diagnostics capable of providing physicians with a powerful tool for creating personalized treatment regimens for patients suffering from serious and difficult-to-treat cancers. For more information on ACLARA please visit the Company's web site at http://www.aclara.com/ . Forward-Looking Statements All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for ACLARA from those projected. Those factors include risks and uncertainties relating to the performance of our products, anticipated progress in commercialization of our eTag(TM) assay system; the potential for use of our eTag assays in clinical development programs; the potential for use of our eTag assays as diagnostic tests; our ability to successfully conduct clinical studies and the results obtained from those studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; our ability to develop organizational capabilities suitable for the further development and commercialization of our eTag assays; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; technological approaches of ACLARA and our competitors; our pending merger with ViroLogic, Inc., including the risk that the closing conditions or the merger may not be satisfied and the merger may not be completed, and costs related to the proposed merger; and other risk factors identified in our Form 10-Q for the quarter ended March 31, 2004 as filed with the Securities and Exchange Commission. DATASOURCE: ACLARA BioSciences CONTACT: investors, Alfred Merriweather, VP, Finance and CFO of ACLARA BioSciences, +1-650-210-1200, or ; or Steven Cragle or Jennifer Viera of Schwartz Communications, +1-415-512-0770, or +1-781-684-0770, or at ASCO, +1-415-845-1256, or +1-617-875-7506, or , for ACLARA BioSciences Web site: http://www.aclara.com/

Copyright